<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067428</url>
  </required_header>
  <id_info>
    <org_study_id>162034</org_study_id>
    <nct_id>NCT03067428</nct_id>
  </id_info>
  <brief_title>Effects of Fructose Restriction on Liver Steatosis</brief_title>
  <acronym>FRUITLESS</acronym>
  <official_title>Effects of Fructose Restriction on Liver Steatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) is an emerging health problem as it can lead to end
      stage liver failure and cardiovascular complications. Diet play an important role in the
      development of NAFLD. Many studies have addressed the effects of added fructose on NAFLD. To
      date, little attention has been paid to the effects of a diet devoid of fructose. Therefore,
      the investigators aim to study the effects of fructose restriction on hepatic fat
      accumulation and vascular function using a double-blind randomized placebo-controlled design.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind, randomized controlled trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intrahepatic triglyceride content</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessed by magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in arterial stiffness</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessed by pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessed by laser doppler flowmetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessed by reactive hyperemia peripheral arterial tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessed by plasma biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose metabolism</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessed by a standard 75-gram oral glucose tolerance test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Glucose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as glucose powder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fructose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as fructose powder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>Participants will adhere to a fructose restricted diet for a period of six weeks (&lt;7.5 grams/meal and/or &lt;10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as glucose powder three times daily during the meal.</description>
    <arm_group_label>Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fructose</intervention_name>
    <description>Participants will adhere to a fructose restricted diet for a period of six weeks (&lt;7.5 grams/meal and/or &lt;10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as fructose powder three times daily during the meal.</description>
    <arm_group_label>Fructose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Body mass index ≥ 28 kg/m2

          -  Fatty liver index ≥ 60

          -  Fructose intake ≥45 grams/day

        Exclusion Criteria:

          -  Medical history of liver disease

          -  (History of) excessive alcohol consumption (defined as &gt; 2 units/day for women, and &gt;
             3 units/day for men)

          -  Major change in weight and/or physical activity prior to the study

          -  Use of glucose lowering drugs

          -  Recent illness

          -  Pregnancy and/or lactation

          -  Contraindications for magnetic resonance imaging

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martijn CG Brouwers, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nynke Simons, MD</last_name>
    <phone>0031433882138</phone>
    <email>n.simons@maastrichtuniversity.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6200 MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nynke Simons, MD</last_name>
      <phone>0031433882138</phone>
      <email>n.simons@maastrichtuniversity.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fructose</keyword>
  <keyword>Diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

